secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-07-16T12:06:47+00:00
Accession:  0001193125-26-305418
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene chairman Glickman resigns; Heffernan appointed chair; BLA submission planned for 2H 2026
--------------------------------------------------------------------------------

- Dr. Richard Glickman resigned as director and chairman effective July 15, 2026; no disagreement.
- Michael Heffernan appointed as chairman; he has over 30 years biopharma experience.
- Pre-BLA meeting with FDA and BLA submission for detalimogene planned for 2H 2026.
- Potential FDA approval of detalimogene in 2027.
- Detalimogene is being evaluated in Phase 2 LEGEND trial for high-risk NMIBC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/0001193125-26-305418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526305418/engn-20260715.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-305418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer